EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria

Ditte Georgina Zhang iD, Mia-Louise Nielsen, Jennifer Astrup Sørensen, Somaia Naassan iD, Christian Vestergaard, Emek Kocatürk iD, Zarqa Ali iD, Jacob P Thyssen iD, Alexander Egeberg, Simon Francis Thomsen

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20737 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Ditte Georgina Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU), but strategies and predictors for guiding long‐term management and discontinuation remain limited.

Objectives

To examine real‐world treatment patterns, including dosing modifications and discontinuation, and identify potential predictive factors for these outcomes.

Methods

This was a retrospective, observational, real‐life study of adult patients with CSU treated with omalizumab at a Urticaria Center of Reference and Excellence (UCARE) in Copenhagen, Denmark, between May 20, 2015, and April 4, 2024. The Kaplan‐Meier estimator was used to visualize time to discontinuation and dose escalation/reduction (using standard label dosing as reference), and Cox‐regressions with hazard ratios (HR) were used to investigate potential predictive variables.

Results

Of 430 patients initiated on omalizumab, 139 (32.4%) escalated treatment, 161 (37.5%) reduced treatment, and 90 (21.0%) discontinued treatment directly from the standard dose. The median survival time for dose escalation was 2 years (95% CI: 1.17–3.55), and the strongest predictor was a positive basophil histamine release assay (BHRA) (HR: 2.79, 95% CI: 1.69–4.61). Fast treatment response (HR: 0.50, 95% CI: 0.33–0.75) and higher baseline UCT scores (HR: 0.89, 95% CI: 0.82–0.97) decreased the risk of dose escalation. The median survival time to dose reduction was 1.2 years (95% CI: 0.98–1.49) and was more likely in males (HR: 1.68, 95% CI: 1.13–2.50) and patients with fast treatment response (HR: 1.66, 95% CI: 1.12–2.48). Median survival time to discontinuation (all reasons) of omalizumab was 3 years (95% CI: 2.35–3.64).

Conclusions

A considerable proportion of patients with CSU require modifications to the recommended omalizumab dosing regimen. A positive BHRA was the strongest predictor for dose escalation, while male sex and fast treatment response were the strongest predictors for dose reduction. Our study highlights the need for individualized strategies in managing CSU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedAgedDose-Response Relationship, DrugDenmark

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
  • Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
  • Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
  • Bahçeşehir University School of Medicine, Department of Dermatology, Istanbul, Turkey.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Ditte Georgina Zhang, Somaia Naassan, Emek Kocatürk, Zarqa Ali, Jacob P Thyssen

Zitieren

APA

Zhang, D. G., Nielsen, M. L., Sørensen, J. A., Naassan, S., Vestergaard, C., Kocatürk, E., Ali, Z., Thyssen, J. P., Egeberg, A., & Thomsen, S. F. (2025). Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20737

Vancouver

Zhang DG, Nielsen ML, Sørensen JA, Naassan S, Vestergaard C, Kocatürk E, et al. Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20737

BibTeX
@article{Zhang2025,
  author = {Zhang, Ditte Georgina and Nielsen, Mia-Louise and Sørensen, Jennifer Astrup and Naassan, Somaia and Vestergaard, Christian and Kocatürk, Emek and Ali, Zarqa and Thyssen, Jacob P and Egeberg, Alexander and Thomsen, Simon Francis},
  title = {Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20737}
}
Kostenlos starten →